Business
Prothena Reports Third Quarter 2025 Financial Results and Business Highlights
DUBLIN, November 06, 2025--Prothena today reported financial results for the third quarter and first nine months of 2025 and provided business highlights.
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3612,"height":1160,"url":"https://media.zenfs.com/en/business-wire.com/f2b0c4b2926368dc49baedc8931b7055"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/X5.nH4gHja6M8YiwzSn8Hw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/f2b0c4b2926368dc49baedc8931b7055","width":960,"height":308},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/PMPEYC0bZuY67nFEAOrhug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/f2b0c4b2926368dc49baedc8931b7055","width":1200,"height":385}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Net cash used in operating and investing activities was $40.6 million and $140.4 million for the third quarter and first nine months of 2025, respectively; quarter-end cash and restricted cash position was $331.7 million","length":220,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Roche to initiate the Phase 3 PARAISO clinical trial evaluating prasinezumab, a potential first-in-class anti-alpha-synuclein antibody, for early-stage Parkinson's disease by end of 2025","length":190,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Novo Nordisk initiated the Phase 3 CLEOPATTRA clinical trial evaluating coramitug, a potential first-in-class amyloid depleter, for ATTR amyloidosis with cardiomyopathy","length":168,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Novo Nordisk to present Phase 2 results for coramitug during a late-breaking session at the American Heart Association Scientific Sessions on November 10, 2025","length":159,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Bristol Myers Squibb obtained Fast Track designation from the U.S. FDA for BMS-986446 (PRX005), an anti-MTBR-tau-targeting antibody, for the treatment of Alzheimer’s disease","length":173,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Prothena will convene an Extraordinary General Meeting on November 19, 2025 to obtain shareholder approval on a proposal reducing share capital to create distributable reserves to support a share redemption program to be conducted in 2026 if deemed appropriate","length":260,"tagName":"p"...